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Abstract
Objectives: The aim of this study was to assess whether biological markers can provide prognostic
information additional to that supplied by the clinical risk score (CRS) in patients with colorectal liver
metastases.
Methods: A retrospective review of a prospectively maintained database was conducted. Patients
selected for this study were treated between 1996 and 2011 with potentially curative liver surgery.
Expressions of p53, Ki-67 and thymidylate synthase were assayed using immunohistochemical tech-
niques on tissue microarrays.
Results: A total of 98 (24%) of 406 patients met the inclusion criteria. The median follow-up was
103 months. Analysis revealed a correlation between p53 protein overexpression and high CRS (P =
0.058). Following multivariate analysis, only high CRS remained as an independent negative prognostic
predictor of survival (P = 0.018), as well as an indicator of early recurrence of disease (P = 0.010). Of the
biological markers investigated, only Ki-67 overexpression was identified as a positive predictor of
survival on multivariate analysis (P = 0.038).
Conclusions: Ki-67 overexpression was a positive predictor of survival. Only high CRS remained an
independent negative prognostic predictor.
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Introduction
Liver resection is the only treatment option providing longterm
survival in patients with colorectal liver metastases (CLM).1
However, recurrent disease subsequently develops in approxi-
mately 75% of resection patients.2 Currently there are a number of
criteria to identify patients who are at risk of developing recur-
rence after potentially curative liver resection for CLM. Many
clinical prognostic markers have been investigated and several
prognostic scoring systems have been proposed.3–5 The clinical
risk score (CRS), published by Fong et al.,5 has been found to be a
useful clinical tool in several studies.6,7
However, variations observed in the longterm survival of
patients with similar prognostic factors suggest that other factors
may also be at play in determining survival after resection of CLM.
More recently, there has been increased interest in identifying
molecular markers that may help to better define patients at risk
for recurrence.8
The present study investigated the biological markers p53,
Ki-67 and thymidylate synthase (TS). p53 is a tumour suppressor
gene with a central role in controlling both the cell cycle and the
apoptotic machinery.9 Ki-67 is associated with cell proliferation.10
Thymidylate synthase is an enzyme integral to DNA synthesis and
is the target of fluorouracil (FU)-based chemotherapy.11 The pre-
sumed relationships among p53, Ki-67 and TS expression and
prognosis have been studied previously, but the results are
contradictory.8–12
The aim of this study was to evaluate the potential prognostic
value of p53, Ki-67 and TS expression in predicting actual and
disease-free survival after the radical resection of CLM.
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Materials and methods
Clinical information
This study was approved by the National Medical Ethics Commit-
tee of the Republic of Slovenia. Study subjects were identified
from a prospectively maintained database of 406 patients who
underwent liver resections and/or local ablative procedures for
CLM from January 1996 to December 2011 at the Department of
Abdominal and General Surgery, University Medical Centre
(UMC) Maribor. The database comprised data on preoperative
assessment, surgical treatment, postoperative course, histopathol-
ogy and longterm follow-up. Criteria for resectability required
candidates to be medically fit for major surgery, to show no evi-
dence of disseminated disease, and to be amenable to a resection
strategy that encompassed all liver disease, leaving remnant liver
adequate for recovery. The diagnosis of CLM was confirmed by
histopathology.
All patients in the database who submitted to liver resection in
the period from 1996 to 2006 were selected and included in the
study if they fulfilled the inclusion criteria. Study inclusion criteria
are shown in Fig. 1.
A total of 14 routinely available clinical variables were analysed.
Preoperative clinical variables included patient demographics
(age, sex), patient performance status [defined according to the
American Society of Anesthesiologists (ASA) score], primary
tumour site, synchronous or metachronous metastases, chemo-
therapy before liver resection, and CRS as defined by Fong et al.5
The CRS is derived by awarding one point for each of five factors:
(i) node-positive primary colorectal cancer; (ii) a disease-free
interval of <12 months; (iii) the presence of more than one
tumour; (iv) a largest tumour size of >5 cm, and (v) a pre-
hepatectomy carcinoembryonic antigen (CEA) level of >200 ng/
ml. Liver surgery-related clinical variables included the temporal
relationship of the surgical procedure (colorectal/liver surgery),
the extent of liver resection, bilateral resection, and complications
after liver resection. Histopathology-related clinical variables
included the presence of extrahepatic disease, resection margin
status, and grade of metastases.
Follow-up
Patients were followed at outpatient clinics at periodic intervals.
Follow-up included clinical, biochemical (CEA test), thoracic
X-ray, and liver ultrasound or computed tomography (CT) evalu-
ations every 3 months for the first 2 years and every 6 months
thereafter. Metastatic recurrence was diagnosed by CEA rise and
CT. From 1999, positron emission tomography (PET) scans were
performed in selected patients and from 2004 PET-CT scans were
carried out in selected patients. In any uncertainty, histology
was required. Follow-up data were obtained from outpatient
follow-up and from the National Cancer Register of Slovenia.
Patient follow-up data included details of dates of disease recur-
rence and death, site of recurrence, further therapy (e.g. systemic
therapy, surgery), and cause of death. Recurrences were classified
as hepatic, extrahepatic or combined. Recurrent disease was
treated according to standard clinical practice and included
surgery and/or chemotherapy whenever possible. The principles
behind the selection criteria for resection of recurrent CLM were
the same as those for the initial hepatectomy. Patients for whom
no further information could be obtained were considered as lost
to follow-up and excluded from this study. All patients were fol-
lowed until their death or until December 2011.
Chemotherapy
Perioperative chemotherapy was not administered as a standard
treatment protocol in patients with CLM. In general, patients with
colorectal cancer and Union for International Cancer Control
(UICC) stage III and IV disease were treated with adjuvant
chemotherapy at the discretion of the medical oncologist.
Chemotherapy included fluoropyrimidine-based therapies
alone or in combination with oxaliplatin or irinotecan. The dif-
ferent chemotherapy protocols included oral capecitabin admin-
istered as a single agent, and the MAYO (fluorouracil and
leucovorin), FOLFOX (oxaliplatin, fluorouracil and leucovorin),
XELOX (capecitabin and oxaliplatin), XELIRI (capecitabin and
irinotecan) and FOLFIRI (irinotecan, fluorouracil and leucov-
orin) protocols, respectively.
406  liver resections and/or local
ablative procedures for CLM
Study inclusion criteria
109 patients
- First liver resection for CLM
- Potentially curative R0 resection (histological
demonstration of clear resection margins and no
residual disease)
- No combination of resection with RFA
- No adjuvant chemotherapy following R0 surgery
- No cetuximab or bevacizumab perioperatively
- Follow-up period of surviving patients > 5 years
Additionally excluded
11 patients
- Postoperative mortality: 3 patients
- Mortality after second liver resection: 1 patient
- Complete necrosis of metastases: 2 patients
- Lost to follow-up: 1 patient
- Tissue lost on tissue microarray: 4 patients
98 patients for analysis
Figure 1 Study inclusion criteria and patient flow. CLM, colorectal
liver metastasis; R0, negative margin; RFA, radiofrequency ablation
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In the last year of the period under study (2006), bevacizumab
or cetuximab were added in selected patients; these patients were
excluded from the current analyses.
Basically, no adjuvant chemotherapy was given after negative
margin (R0) resection of CLM. Patients selected for this study
received no adjuvant chemotherapy after liver resection.
Histopathology and construction of
tissue microarrays
All liver metastases specimens were analysed routinely after liver
resection for histology type, number of tumour nodules, size of
the largest nodule and margin status. Histological grading (well,
moderately or poorly differentiated) was performed according
to the World Health Organization (WHO) classification.13 Addi-
tional immunohistochemistry (IHC) examinations were per-
formed retrospectively on archived tumour specimens from these
patients for the purposes of this study. Expressions of the p53,
Ki-67 and TS markers were determined using IHC staining of
constructed tissue microarrays.
Representative formalin-fixed and paraffin-embedded resec-
tion specimens of liver metastases were selected from the archive
of the Department of Pathology, UMC Maribor. One representa-
tive tissue block of a metastasis from each patient was used. Firstly,
a haematoxylin and eosin (H&E) stain of each specimen was
reviewed by a pathologist and the areas of interest (i.e. viable,
metastasized colorectal tumour cells in the liver) were marked. For
each patient, representative tumour blocks were selected and used
for the construction of tissue microarrays. To avoid possible intra-
tumoral heterogeneity, three cores of different areas of the tumour
from each donor tissue block were sampled. Three recipient tissue
blocks were made in this way. Tumour samples were arrayed
as previously described.14,15 The MTA-1 manual tissue arrayer
(Beecher Instruments, Inc., Sun Prairie, WI, USA) was used to
create the microarrays. The punch size was set at 0.6 mm. Sections
of 2–3 mm in thickness were cut from each tissue microarray
paraffin block and placed on SuperFrost/Plus object slides.
Immunohistochemical staining of biological markers
Immunohistochemical staining of the tissue microarrays was per-
formed with the Ventana BenchMark XT automated slide stainer
(Ventana Medical Systems, Inc., Tucson, AZ, USA). The sections
were deparaffinized, rehydrated and processed with the ultraView
Universal DAB Detection Kit (Ventana Medical Systems, Inc.) for
p53 and Ki-67. Thymidylate synthase was processed using the
iVIEW DAB Detection Kit (Ventana Medical Systems, Inc.). Sec-
tions were submitted to antigen retrieval in the automated slide
stainer for 60 min with Cell Conditioning 1 (CC1; Ventana
Medical Systems, Inc.). The slides were then incubated with an
appropriately diluted primary antibody. Mouse antihuman
monoclonal antibodies to p53 (clone DO-7, 1 : 150) (Dako
Denmark A/S, Glostrup, Denmark), Ki-67 (Mib-1, 1 : 100) (Dako
Denmark A/S) and TS (clone TS106, 1 : 25) (Dako Denmark A/S)
were used. Diaminobenzidine was used as the chromogen, and
haematoxylin II, a bluing reagent, was used as the nuclear coun-
terstain. Positive controls included tumour cells with high protein
expression (for all antibodies tested). Negative controls were pre-
pared by omitting the primary antibody.
Immunohistochemical scoring
Using a light microscope, patients represented by materials of
which at least two of the three tissue cores showed analysable
staining were selected for inclusion in the final analysis. Patients
represented by materials of which only one or no cores showed
analysable staining were regarded as lost from this study. All speci-
mens were analysed by a pathologist and investigator.
Expressions of p53 and Ki-67 were evaluated by scoring the
percentage of positively stained nuclei of the malignant cells in
each tissue. Specimens were considered positive for p53 and Ki-67
when >50% of tumour cells were stained.
For TS, the intensity of cytoplasm staining of malignant cells in
each tissue sample was taken into account because these proteins
were expressed in almost all tumour cells. Definition of TS 106
staining intensity was based on a visual grading scale of 0–3.
Intensity levels 0 and 1 were grouped together as representing
low-intensity staining; levels 2 and 3 were grouped as representing
intermediate or high-intensity staining.
Any scoring discrepancies (approximately 10% of cases) were
resolved by consensus.
Outcome
Actual survival (AS) was defined as the interval between the date
of resection of CLM and the date of death (or the date of the last
follow-up in surviving patients). Disease-free survival (DFS) was
calculated from the date of liver resection to the date of intra-
and/or extrahepatic recurrence (or the date of the last follow-up
in surviving patients without recurrence). Longterm survivors
were considered to be those patients who remained alive at >5
years after first liver resection. Early death was defined as death
within 2 years of liver surgery. Patients who achieved DFS of >5
years after first liver resection were considered to be longterm
disease-free survivors. Early disease recurrence was represented by
any disease recurrence within 2 years of liver surgery.
Statistical analysis
IBM spss for Windows Version 19.0 (IBM Corp., Armonk, NY,
USA) was used for statistical computations.
Differences in the frequency distributions of p53, Ki-67 and TS
reactivity in relation to other clinical characteristics were tested
using the chi-squared test for categorical variables (Pearson’s or
Fisher’s exact test when appropriate, two-tailed in all instances).
Continuous variables were analysed using Student’s t-test for
independent samples or the Mann–Whitney U-test if the criteria
for parametric testing were not met. A difference with a P-value of
<0.05 was considered statistically significant.
All survival probabilities were estimated using Kaplan–Meier
survival analysis. The effect of each of the markers and 14 rou-
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tinely available clinical characteristics on survival was evaluated
using the log-rank test. As only specimens from patients operated
before January 2007 were used, 5-year AS is provided.
Cox proportional hazards models were used for multivariate
analysis. All three biological markers (p53, Ki-67 and TS), regard-
less of the results of bivariate analysis, and significant clinical
variables from bivariate analysis (P < 0.10) were included. Model
building was based on a backward stepwise algorithm with P <
0.10 as the exclusion criterion, in which the likelihood ratio was
used as a test statistic.
Results
Study population
Of the 406 patients identified, 98 (24%) met the inclusion criteria.
Their median age was 62 years (range: 27–78 years) and 56 (57%)
patients were male. A total of 48 (49%) patients had concomitant
systemic disease (ASA class 2 or 3). The primary tumour site was
the colon in 48 (49%) and rectum in 50 (51%) patients; 41
patients (42%) had shown synchronous and 57 (58%) had shown
metachronous metastases.
Fluoropyrimidine-based chemotherapy had been administered
in the adjuvant setting following primary colorectal resection in
75 (76%) patients. Forty (41%) patients had received systemic
chemotherapy, either for measurable metastatic disease within the
6 months prior to liver resection or in the adjuvant setting follow-
ing primary resection. A total of 23 (23%) patients had been
chemotherapy-naïve.
All patients were found to have a CRS within the range of 0–4;
no patient had a CRS of 5. Descriptive statistics for each of the
individual clinical risk factors from which the CRS is derived were
as follows: 57 (58%) patients had node-positive primary colorec-
tal cancer; the median disease-free interval was 12 months (range:
0–164 months); the median number of hepatic metastases
removed was one (range: one to eight); 46 (47%) patients had
more than one metastasis; the median size of each patient’s largest
tumour was 4.0 cm (range: 0.8–12.0 cm), and the median pre-
hepatectomy CEA level was 17 ng/ml (range: 0.3–1348 ng/ml).
Eleven (11%) patients underwent simultaneous liver and color-
ectal surgery. A total of 25 (26%) patients were operated during
1996–2001 and 73 (74%) were operated during 2002–2006.
To achieve a radical resection, extended hepatectomies were
performed in six (6%) patients, formal hemi-hepatectomies in 12
(12%) patients, segment-oriented resections in 62 (63%) patients
and non-anatomical resections in 18 (18%) patients. Major liver
surgery (trisegmentectomy or greater) was performed in 39 (40%)
patients and bilateral resection in 34 (35%) patients. Resections
were performed by four different surgeons.
Complications after liver surgery occurred in 13 (13%)
patients.
Eleven (11%) patients presented with extrahepatic disease,
which was radically resected in addition to liver surgery with
histological demonstration of no residual disease. The median
resection margin in liver metastases resections was 2.0 mm
(range: 0.1–20.0 mm). Liver metastases were graded as well dif-
ferentiated in 27 (28%) patients, moderately differentiated in 69
(70%) patients, and poorly differentiated in two (2%) patients.
A total of 52 (53%) metastases stained positive for p53 protein
and 27 (28%) stained positive for Ki-67 protein. Immunostaining
for TS was low in 29 (30%) and high in 69 (70%) of the 98
metastatic samples.
The median follow-up in surviving patients was 103 months
(range: 61–195 months). Rates of 5-year AS and 10-year overall
survival (OS) were 34.5% and 24.3%, respectively, with median
survival of 36 months. Actual 5-year DFS was 20.4%, with a
median DFS of 13 months.
Recurrent disease
Of the 98 patients submitted to potentially curative liver resection,
72 (73%) developed recurrent disease and, of these, 33 (34%)
patients underwent repeat hepatic resection (one to six repeat
resections). In 59 (82%) of 72 patients, recurrence was diagnosed
within 2 years of the first liver surgery of metastases. The pattern
of recurrence in these 72 patients was as follows: in 20 (28%)
patients, recurrence was confined to the liver; in 20 (28%)
patients, recurrence was confined to an extrahepatic location only,
and in 32 (44%) patients, intra- and extrahepatic metastases were
present.
A total of 29 (30%) longterm survivors were identified. Another
29 (30%) patients were defined as belonging to the early death
group. Sixteen (16%) longterm disease-free survivors were iden-
tified. A total of 59 (60%) patients were identified as suffering
early disease recurrence.
Correlations of p53, Ki-67 and TS expression
and survival
Chi-squared analysis revealed a relationship between p53 protein
positive staining and high CRS (P = 0.058). There were no asso-
ciations between Ki-67 or TS expression, and CRS or any of the
other clinical variables investigated (data not shown). Analysis of
the interrelationships among the three biological markers showed
no associations (data not shown).
The results of analysis of p53, Ki-67 and TS overexpression in
patients with differing outcomes following liver resection are
shown in Table 1.
Data on AS and DFS in patients whose tumour samples stained
positive or negative, respectively, for the biological markers are
shown in Table 2.
Clinical variables associated with significant (P < 0.05) or mar-
ginally significant (P 0.10) differences in AS or DFS in bivariate
analysis are shown in Table 2.
The following clinical variables showed no significant (P > 0.2)
associations with any of the study endpoints: sex; ASA class;
primary tumour site; synchronous or metachronous metastases;
chemotherapy before liver resection; temporal relationship of sur-
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gical procedure; extent of liver resection; bilateral resection; com-
plications after liver resection, and resection margin (2-mm cut-
off). These data are not shown.
Multivariate results
The following non-correlated factors were included in multivari-
ate survival analyses: age; CRS; grade of metastases; extrahepatic
disease; resection margin (1-mm cut-off), and all investigated bio-
logical markers. Findings of the multivariate analysis for each
endpoint (AS and DFS) are summarized in Table 3. Values for
non-significant variables were taken from the last step in a step-
wise regression model in which they were still included.
Discussion
There is an ongoing effort to translate basic knowledge about
biological markers into clinical use. An important advantage of
Table 1 Proportions of patients with p53, Ki-67 and thymidiylate synthase (TS) overexpression in groups with differing outcomes following
liver resection, showing actual survival and actual disease-free survival
Variable Earlya
death,
n
Longtermb
survivors,
n
P-value
(c2 test)
Earlya
recurrence,
n
Longtermb
disease-free
survivors, n
P-value
(c2 test)
p53 19/29 12/29 0.113 34/59 8/16 0.777
Ki-67 6/29 11/29 0.248 12/59 7/16 0.101
TS 24/29 19/29 0.230 43/59 12/16 1.000
aWithin 2 years.
bOver 5 years.
Table 2 Bivariate analysis of clinical variables and biological markers in relation to 5-year actual survival (AS) and 5-year actual disease-free
survival (DFS)
Variable Patients
(n = 98),
n (%)
Median AS,
days
Actual
5-year
survival, %
P-value
(log-rank
test)a
Median
DFS, days
Actual
5-year
DFS, %
P-value
(log-rank
test)a
Age 0.108 0.829
<62 years 47 (48%) 1412 42.6% 420 17.0%
62 years 51 (52%) 809 26.8% 382 23.5%
CRS 0.041 0.007
Low 62 (63%) 1295 38.5% 568 24.2%
High 36 (37%) 794 24.3% 279 13.9%
ED 0.257 0.011
Absent 87 (89%) 1239 35.3% 423 23.0%
Present 11 (11%) 764 27.3% 297 0%
RM 0.174 0.093
1 mm 29 (30%) 850 27.6% 306 13.8%
>1 mm 69 (70%) 1295 37.2% 568 23.2%
Grade of metastases 0.058 0.099
I 27 (28%) 1318 40.4% 790 25.9%
II or III 71 (72%) 914 30.6% 342 18.3%
p53 0.195 0.317
+ 52 (53%) 869 26.8% 344 19.2%
- 46 (47%) 1460 43.1% 476 21.7%
Ki-67 0.159 0.166
+ 27 (28%) 1460 48.1% 790 29.6%
- 71 (72%) 881 29.3% 350 16.9%
TS 0.825 0.935
+ 69 (70%) 1076 34.3% 350 23.8%
- 29 (30%) 1274 34.5% 529 13.8%
aValues in bold are significant at P < 0.05.
CRS, clinical risk score; ED, extrahepatic disease; RM, resection margin; TS, thymidiylate synthase.
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this study is its inclusion of a homogeneous group of patients. All
patients were uniformly treated with liver resection and selected
for the study appropriately in order to avoid any potential biases
in defining the prognostic values of biological markers. Moreover,
because all patients were operated before January 2007, a minimal
follow-up period of 5 years was obtained, with a median
follow-up of 103 months. Therefore, the survival analysis is based
on actual data rather than on estimations that form the basis of
actuarial survival. To maximize the potential biological difference,
two groups of patients with opposite outcomes following liver
resection were evaluated, as proposed previously by D’Angelica
et al.16
The actual 5-year and actuarial 10-year survival of patients
included in this study were 34.5% and 24.3%, respectively, with
median survival of 36 months. Although all patients underwent a
potentially curative resection, 73% of them subsequently devel-
oped recurrent disease. Reported 5-year OS data in some modern
series reaches 60% in selected patients.17–20 However, the current
study presents actual rather than actuarial survival data. Moreo-
ver, patients with prognostic factors known to be adverse (extra-
hepatic disease) were included in the analysis. Finally, these
patients underwent resection of CLM before the introduction of
modern targeted therapy with bevacizumab or cetuximab.
Other than CRS, the present study found none of the variables
investigated had any consistent influence on AS or DFS. Patients
with a high CRS (3) fared worse after resection than those with
a low CRS (0–2), as evidenced by a lower median AS (26 months
versus 43 months; P = 0.041), as well as a lower DFS (9 months
versus 19 months; P = 0.007).
For the construction of tissue microarrays, three cores of dif-
ferent areas of the metastasis from each donor tissue block were
sampled. It should be noted that only a single metastasis from
each patient was investigated, although 47% of patients in the
current series had multiple tumours. However, in a series of 82
patients and 143 investigated CLM, Menon et al. found a very high
concordance of biological markers in those patients in whom
multiple metastases were available.21
In the present series, a correlation between p53 protein overex-
pression and high CRS was found (P = 0.058). The number of
patients with p53 overexpression in the early death group (65%)
was higher than that in the longterm survival group (41%); this
difference was marginally significant (P = 0.113). Patients with
overexpression of p53 had shortened survival as well as DFS, but
the difference was not statistically significant. Subjectivity in
scoring and the use of different antibodies across trials reported in
the literature make it difficult to compare the findings of separate
trials; findings on the role of p53 protein in CLM in relation to
prognosis are variable.21–29 The confusion on the prognostic
importance of p53 is no less in published series examining the
association of TP53 gene mutation status in CLM.12,30–33
The most important and unexpected finding of the present
study was the identification of Ki-67 overexpression as a positive
predictor of survival. This contradicts findings reported in several
published series, in which a high Ki-67 score is associated with a
worse outcome.34–37 In the study reported by Petrowsky et al.,
patients with high Ki-67 scores (50%) had significantly shorter
median survival compared with those with low scores.35 However,
measures of proliferation have not always demonstrated a signifi-
cant association with clinical outcome.16,27 Moreover, recently a
correlation between slow proliferation and high aggressiveness of
colorectal cancer was demonstrated.38
The current study used a 50% cut-off for defining Ki-67 protein
positive phenotypes, as proposed by several previous authors.34–37
There were more Ki-67 positive patients among the longterm
survivors, but no correlation between Ki-67 score and CRS was
found. The proportion of Ki-67 positive patients was higher in
longterm disease-free survivors (P = 0.101). Moreover, patients
with Ki-67 overexpression lived longer, as demonstrated by the
results of multivariate analysis (P = 0.038). As Ki-67 positivity was
a predictor of AS, but not a predictor of DFS, the present authors
speculate that Ki-67 positivity may have some impact on further
therapies administered subsequent to disease recurrence.
However, no correlation was found between the administration of
repeat liver procedures and/or chemotherapy for recurrence and
Ki-67 status (data not shown).
Findings on TS expression provided no clinical information.
This result contradicts the findings of prior reports which have
demonstrated a significantly worse outcome in CLM patients
Table 3 Cox regression analyses. Variables that remained in the final
model with P < 0.05 were identified as predictors of survival
HR 95% CI for HR P-valuea
Actual survival
Age 62 years 1.54 0.95–2.48 0.075
High CRS (3) 1.78 1.10–2.89 0.018
ED present 1.15 0.55–2.43 0.699
RM of  1 mm 1.31 0.79–2.17 0.285
Grade of metastases II or III 1.73 0.98–3.03 0.055
p53+ 1.35 0.81–2.22 0.239
Ki-67 + 0.82 0.68–0.98 0.038
TS+ 1.07 0.63–1.80 0.789
Disease-free survival
Age 62 years 1.11 0.70–1.76 0.650
High CRS (3) 1.81 1.15–2.86 0.010
ED present 2.11 1.09–4.07 0.025
RM of  1 mm 1.26 0.76–2.09 0.371
Grade of metastases II or III 1.54 0.92–2.56 0.096
p53+ 1.18 0.74–1.88 0.492
Ki-67 + 0.88 0.73–1.05 0.161
TS+ 0.97 0.59–1.60 0.927
aValues in bold are significant at P < 0.05.
HR, hazard ratio; 95% CI, 95% confidence interval; CRS, clinical risk
score; ED, extrahepatic disease; RM, resection margin; TS, thymidiylate
synthase.
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whose tumours have shown high TS expression.22,32,39 However,
several reports have found no association between TS scores and
clinical outcome.16,33,40 In the current study, evaluation of the
interrelationships among p53, Ki-67 and TS expression showed no
associations.
The present study is subject to a number of limitations. The first
involves its sample size. Although the study included 98 patients,
numbers were relatively low when the patients were divided into
subgroups. The inclusion of larger cohorts of patients might
improve the strength of further studies. Secondly, IHC is a semi-
quantitative assay. For all marker expressions, cut-offs for positive
phenotypes were determined according to the literature. Using
different cut-off values may alter the conclusions of any study using
IHC.A standardized method of assessing the degree of positivity or
negativity of staining would facilitate the comparison of results
across different studies. Thirdly, an important factor that did not
influence the outcome was the use of chemotherapy. There were no
standard protocols for chemotherapy across the study population,
although 76% of the study patients had received fluoropyrimidine-
based chemotherapy prior to liver surgery (either for measurable
metastatic disease or in the adjuvant setting following primary
resection). Finally, 34% of patients in this series underwent repeat
hepatic resection. The inclusion of these patients may skew statis-
tical analysis regarding AS because these patients are likely to
achieve better survival as a result of treatable recurrences.
In conclusion, Ki-67 overexpression was identified as a positive
predictor of survival in a homogeneous group of patients. More
extensive studies will be required to determine the clinical rel-
evance of biological markers, which should be assessed singly and
in combinations.
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